AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. HOOD
9. DFTX
10. IBM

Go back to AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
AbbVie (NYSE: ABBV) Delayed: 230.01 +13.52 (6.25%)
Previous Close $216.49    52 Week High $68.12 
Open $221.94    52 Week Low $50.71 
Day High $232.32    P/E 49.89 
Day Low $221.94    EPS $4.61 
Volume 9,912,419       

Immunogen, Inc. (NASDAQ: IMGN) Delayed: 31.25 --0 (-0%)
Previous Close $31.25    52 Week High $14.22 
Open $240.83    52 Week Low $1.51 
Day High $31.25    P/E N/A 
Day Low $31.25    EPS $-0.36 
Volume 670,938